Larimar Therapeutics to Present Nomlabofusp Data at International Congress for Ataxia Research
Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced that interim clinical data from its ongoing open‑label study of long‑term daily nomlabofusp administration, along with new plasma lipid and gene expression analyses in participants with Friedreich’s ataxia (FA), will be presented at the upcoming International Congress for Ataxia Research (ICAR) 2026. The conference will take place on November 10–13 in [city, country].
The company will deliver three poster presentations at ICAR. These posters will highlight:
- Interim efficacy and safety outcomes from the open‑label nomlabofusp trial in FA patients, including clinical endpoints and patient‑reported outcomes.
- Biomarker results demonstrating changes in plasma lipid profiles that may correlate with therapeutic response.
- Gene expression data revealing molecular pathways affected by sustained nomlabofusp treatment.
Larimar’s focus on developing treatments for rare complex diseases is underscored by this presentation. The company’s platform aims to provide protein replacement therapy for conditions such as Friedreich’s ataxia, a progressive neurodegenerative disorder characterized by ataxia and cardiomyopathy.
The ICAR presentations are expected to provide the scientific community with deeper insights into nomlabofusp’s long‑term effects and its potential to modify disease progression in FA patients. Larimar Therapeutics will remain available for discussion with conference attendees and interested stakeholders.
For further information, visit the company’s website at www.larimartx.com or consult the company’s filings on the Nasdaq exchange.
